Last reviewed · How we verify
NCT05321225
The Level of Blood Brain Barrier Damage Biomarker in Acute Ischemic Stroke
trial testing the level of biomarker in bood in Ischemic Stroke in 1,000 participants. Status unknown.
10 March 2023
Quick facts
| Lead sponsor | Ji Xunming,MD,PhD |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 10 March 2022 |
| Primary completion | 10 March 2023 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- the level of biomarker in bood
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
Sponsor
Ji Xunming,MD,PhD — full company profile →
Who can join
Adults 18 to 80, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hemorrhagic transformation is a common complication of acute ischemic stroke patients . BBB damage is regarded as a major pathophysiological mechanism of hemorrhagic transformation. So, the investigators hypothesis the level of BBB damage biomarker is predictor of intracranial hemorrhage following ischemic stroke.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier.
Teleanu RI, Preda MD, Niculescu AG, Vladâcenco O, et al · · 2022 · cited 122× · PMID 35631573 · DOI 10.3390/pharmaceutics14050987
Verify or expand the search:
- PubMed search for NCT05321225
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of the level of biomarker in bood
Trials testing the same drug.
- NCT05413837 — Anatomical Variation of Cerebral Venous Sinus in Healthy Individuals · unknown
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other Ji Xunming,MD,PhD trials
Trials by the same sponsor.
- NCT05965193 — Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke：Longterm Outcome (OPENS-3L) · Phase 3 · unknown
- NCT05965687 — Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3) · Phase 3 · unknown
- NCT05781880 — Normobaric Hyperoxia Stabilizing Ischemic Penumbra · NA · unknown
- NCT05426707 — Remote Ischemic Conditioning for the Treatment of Resistant Hypertension · NA · unknown
- NCT05289518 — Remote Ischemic Conditioning for the Treatment of Stroke-related Insomnia · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05321225 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ji Xunming,MD,PhD
- Last refreshed: 15 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05321225.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing